亚洲转移性和非转移性非小细胞肺癌生物标志物检测专家共识建议
亚洲肺癌专家针对亚洲非小细胞肺癌(NSCLC)患者,制定非转移性和转移性腺癌及鳞状细胞癌的生物标志物检测共识建议,强调鉴于亚洲EGFR突变患病率较高,EGFR检测应涵盖常见及非常见突变,并讨论了液体活检评估肿瘤生物标志物的作用。
要点
- 亚洲EGFR突变患病率高于其他地区,EGFR检测应涵盖常见及非常见突变。
- 共识建议按非转移性和转移性腺癌及鳞状细胞癌分别给出检测建议。
- 除组织检测外,共识讨论了液体活检评估肿瘤生物标志物的作用。
核心结论
- 该共识为亚洲非转移性和转移性NSCLC患者的生物标志物检测提供了实用性建议。
研究设计与样本
- 由亚洲肺癌专家制定的共识建议,针对在亚洲工作的临床医生,旨在改善患者照护。
主要发现
- 建议分为非转移性和转移性腺癌及鳞状细胞癌。
- 由于亚洲EGFR突变患病率较高,专家强调EGFR检测不仅应包括常见突变(外显子19缺失和L858R替换),还应包括其他非常见EGFR突变。
- 除评估肿瘤组织中的生物标志物外,还讨论了通过液体活检评估肿瘤生物标志物的作用。
关键数值与推荐
- EGFR检测应涵盖常见突变(外显子19缺失和L858R替换)及其他非常见EGFR突变。
- 讨论了EGFR、ALK、ROS1等可操作遗传变异的生物标志物检测方法。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Most published guidelines for genomic biomarker testing in NSCLC reflect the disease epidemiology and treatments readily available in Europe and North America. Nevertheless, 60% of annual global NSCLC cases occur in Asia, where patient characteristics, tumor molecular profiles, and treatments vary greatly from the Western world. For example, mutations in the EGFR occur at a higher prevalence in Asia than in other world regions. Although medical associations such as the International Association for the Study of Lung Cancer, European Society for Medical Oncology, and American Society of Clinical Oncology have described principles for tumor genomic biomarker testing in NSCLC, there is a need for recommendations specific for Asia. METHODS: This report provides consensus recommendations for NSCLC biomarker testing from Asian lung cancer experts for clinicians working in Asia to improve patient care. Biomarker testing approaches for actionable genetic alterations in EGFR, ALK, ROS1, and others are discussed. RESULTS: These recommendations are divided into nonmetastatic and metastatic forms of adenocarcinoma and squamous cell carcinoma. Owing to the higher prevalence of EGFR mutations in Asia, the experts emphasized the need for EGFR testing to include not just common mutations (exon 19 deletions and L858R substitutions) but also other uncommon EGFR mutations. In addition to the assessment of biomarkers in the tumor tissue, the role of assessing tumor biomarkers by liquid biopsy is discussed. CONCLUSION: This consensus provides practical recommendations for biomarker testing in nonmetastatic and metastatic Asian NSCLC patients.
引用
- Mitsudomi T, Tan D, Yang JC, et al. Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia. J Thorac Oncol. 2022. PMID: 36379356. doi:10.1016/j.jtho.2022.10.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。